Dana Investment Advisors Inc. Sells 50,580 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Dana Investment Advisors Inc. lessened its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 51.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,063 shares of the medical research company's stock after selling 50,580 shares during the quarter. Dana Investment Advisors Inc.'s holdings in IQVIA were worth $9,248,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in IQV. Private Trust Co. NA lifted its stake in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after purchasing an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its stake in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after acquiring an additional 50 shares during the last quarter. Howard Capital Management Inc. boosted its holdings in IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares during the period. Huntington National Bank grew its position in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company's stock valued at $192,000 after acquiring an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV opened at $186.04 on Thursday. The company has a 50 day moving average of $198.24 and a two-hundred day moving average of $213.66. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $261.73. The company has a market cap of $32.80 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Bank of America lowered their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research note on Friday, December 13th. UBS Group dropped their target price on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 price target for the company. Truist Financial reiterated a "buy" rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.